Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 1
2005 2
2008 1
2009 3
2011 7
2012 8
2013 4
2014 1
2015 6
2016 8
2017 4
2018 5
2019 6
2020 14
2021 9
2022 10
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Results by year

Filters applied: . Clear all
Page 1
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Bardia A, et al. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.
Tumoral heterogeneity of breast cancer.
Roulot A, Héquet D, Guinebretière JM, Vincent-Salomon A, Lerebours F, Dubot C, Rouzier R. Roulot A, et al. Among authors: lerebours f. Ann Biol Clin (Paris). 2016 Dec 1;74(6):653-660. doi: 10.1684/abc.2016.1192. Ann Biol Clin (Paris). 2016. PMID: 27848916 Free article. Review. English.
Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study.
Rugo HS, Lerebours F, Ciruelos E, Drullinsky P, Ruiz-Borrego M, Neven P, Park YH, Prat A, Bachelot T, Juric D, Turner N, Sophos N, Zarate JP, Arce C, Shen YM, Turner S, Kanakamedala H, Hsu WC, Chia S. Rugo HS, et al. Among authors: lerebours f. Lancet Oncol. 2021 Apr;22(4):489-498. doi: 10.1016/S1470-2045(21)00034-6. Lancet Oncol. 2021. PMID: 33794206 Clinical Trial.
Sustainable return to work among breast cancer survivors.
Ruiz de Azua G, Kousignian I, Vaz-Luis I, Di Meglio A, Caumette E, Havas J, Martin E, Martin AL, Querel O, Vanlemmens L, Pistilli B, Coutant C, Cottu PH, Merimeche AD, Lerebours F, Tredan O, Jouannaud C, Levy C, Dumas A, Menvielle G. Ruiz de Azua G, et al. Among authors: lerebours f. Cancer Med. 2023 Sep;12(18):19091-19101. doi: 10.1002/cam4.6467. Epub 2023 Aug 21. Cancer Med. 2023. PMID: 37602836 Free PMC article.
Cognitive change in breast cancer patients up to 2 years after diagnosis.
Lange M, Lefevre Arbogast S, Hardy-Léger I, Rigal O, Le Fel J, Pistilli B, Petrucci J, Lévy C, Capel A, Coutant C, Médeau L, Lerebours F, Vanlemmens L, Brion M, Bourbouloux E, Blain M, Binarelli G, Vaz-Luis I, Giffard B, Querel O, Everhard S, André F, Charles C, Dauchy S, Joly F. Lange M, et al. Among authors: lerebours f. J Natl Cancer Inst. 2023 Mar 9;115(3):322-331. doi: 10.1093/jnci/djac240. J Natl Cancer Inst. 2023. PMID: 36571503 Free PMC article.
Long-Term Longitudinal Patterns of Patient-Reported Fatigue After Breast Cancer: A Group-Based Trajectory Analysis.
Vaz-Luis I, Di Meglio A, Havas J, El-Mouhebb M, Lapidari P, Presti D, Soldato D, Pistilli B, Dumas A, Menvielle G, Charles C, Everhard S, Martin AL, Cottu PH, Lerebours F, Coutant C, Dauchy S, Delaloge S, Lin NU, Ganz PA, Partridge AH, André F, Michiels S. Vaz-Luis I, et al. Among authors: lerebours f. J Clin Oncol. 2022 Jul 1;40(19):2148-2162. doi: 10.1200/JCO.21.01958. Epub 2022 Mar 15. J Clin Oncol. 2022. PMID: 35290073 Free PMC article.
Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.
Balazard F, Bertaut A, Bordet É, Mulard S, Blanc J, Briot N, Paux G, Dhaini Merimeche A, Rigal O, Coutant C, Fournier M, Jouannaud C, Soulie P, Lerebours F, Cottu PH, Tredan O, Vanlemmens L, Levy C, Mouret-Reynier MA, Campone M, Brady KJS, Sasane M, Rice M, Coulouvrat C, Martin AL, Jacquet A, Vaz-Luis I, Herold C, Pistilli B. Balazard F, et al. Among authors: lerebours f. J Natl Cancer Inst. 2023 Sep 7;115(9):1099-1108. doi: 10.1093/jnci/djad109. J Natl Cancer Inst. 2023. PMID: 37434306
Update on inflammatory breast cancer.
Lerebours F, Bieche I, Lidereau R. Lerebours F, et al. Breast Cancer Res. 2005;7(2):52-8. doi: 10.1186/bcr997. Epub 2005 Jan 20. Breast Cancer Res. 2005. PMID: 15743511 Free PMC article. Review.
89 results